InvestorsHub Logo
Followers 22
Posts 888
Boards Moderated 0
Alias Born 05/09/2012

Re: None

Sunday, 02/17/2013 12:04:23 PM

Sunday, February 17, 2013 12:04:23 PM

Post# of 346116
Knowing that the NSCLC trial discrepancies only occurred in the 1mg and placebo group, then the data for the 3mg arm should still remain valid, yes???

The data for the 3mg arm was 13.1 months MOS, overall response rate of 17.9%, and Progression free survival of 4.5 months.

Is that data still outstanding compared to current standard of care??? If so, this would still appear to be a promising investment opportunity IMO... Any thoughtful arguments for or against my thought process would be welcome. TIA.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News